* SAIK-MS Phase II study to start as planned
* TTS Phase II studies:
- renal cancer study started and go-ahead given for start of pancreatic cancer study
* Candidate drug selected for prostate cancer project
* Patent portfolio further strengthened by US patent approval for prostate cancer project
* Profit after financial items of SEK 34.8 million (SEK -419.4 million) for the full year - in line with forecast
